ADC Therapeutics will reduce its global workforce by 17% as part of a strategic reorganization expected to save $10 million annually and support planned regulatory expansion of ZYNLONTA following positive Phase 3 LOTIS-5 results.
Written By: Nalam Karthik, PharmD
Reviewed By: Pharmacally Editorial Team
ADC Therapeutics has announced a strategic reorganization that includes a reduction of approximately 17% of its global workforce, a move expected to generate about $10 million in annualized cost savings while strengthening the company’s focus on key regulatory and commercial priorities for ZYNLONTA® (loncastuximab tesirine-lpyl).
The company said the restructuring is designed to improve operational efficiency, enhance financial flexibility, and better align resources with programs that have the greatest potential to drive future growth. Management believes the initiative will support execution of several upcoming milestones, including a planned regulatory submission seeking to expand the use of ZYNLONTA in diffuse large B-cell lymphoma (DLBCL).
Workforce Reduction to Improve Operational Efficiency
As part of the reorganization, ADC Therapeutics will streamline operations across its global organization while maintaining focus on its core commercial and development priorities. The company expects the workforce reduction to generate approximately $10 million in annualized savings, enabling more disciplined capital allocation and increased investment in strategic growth opportunities.
According to management, the restructuring is intended to position the company for more efficient execution as it advances regulatory activities and seeks to maximize the commercial potential of ZYNLONTA.
LOTIS-5 Supports Planned Label Expansion
A key priority for ADC Therapeutics is advancing ZYNLONTA’s clinical and regulatory development strategy. ZYNLONTA is a CD19-directed antibody-drug conjugate currently approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
The company’s regulatory plans are supported by positive results from the Phase 3 LOTIS-5 (NCT04384484) confirmatory trial, which evaluated ZYNLONTA in combination with rituximab in patients with relapsed or refractory DLBCL. The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival compared with standard immunochemotherapy.
The findings are expected to support efforts to expand ZYNLONTA’s use into an earlier treatment setting and strengthen its position within the evolving DLBCL treatment landscape.
Regulatory Submission Planned
ADC Therapeutics intends to pursue a supplemental Biologics License Application (sBLA) based on the LOTIS-5 results and plans to continue discussions with the U.S. Food and Drug Administration regarding the proposed submission pathway.
The company stated that regulatory execution remains a central focus of its strategy as it seeks to broaden the clinical utility of ZYNLONTA and unlock additional commercial opportunities. Beyond LOTIS-5, ADC Therapeutics continues to generate clinical evidence that could support future development and lifecycle management initiatives for the product.
Additional Clinical Data Expected in 2026
Further clinical updates are expected from both the LOTIS-5 and LOTIS-7 programs. ADC Therapeutics anticipates releasing full data from the Phase 3 LOTIS-5 study as well as comprehensive results from the LOTIS-7 combination study by the end of 2026.
These datasets are expected to provide additional insights into the efficacy and safety profile of ZYNLONTA-based regimens and help inform future regulatory and commercial strategies.
Cash Runway Extends Into 2028
Alongside its development priorities, ADC Therapeutics continues to emphasize financial discipline. As of March 31, 2026, the company reported approximately $231 million in cash and cash equivalents, which it expects will support operations into at least 2028.
Management indicated that the anticipated savings generated through the restructuring will further strengthen the company’s financial position, allowing resources to be concentrated on programs with the highest potential to create long-term value.
Path Forward
Through the strategic reorganization, ADC Therapeutics is seeking to streamline operations, preserve capital, and sharpen its focus on high-impact regulatory and commercial opportunities for ZYNLONTA. With a planned sBLA submission, ongoing FDA engagement, and multiple clinical data readouts expected over the coming months, the company is positioning itself for several potential catalysts that could shape the next phase of growth for its lead oncology asset.
Reference
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.